Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): A randomized, multicenter, phase II trial SAKK 41/07

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 718-725

  Helbling, D ^a   Bodoky, G ^b   Gautschi, O ^c   Sun, H ^d   Bosman, F ^a   Gloor, B ^e   Burkhard, R ^f   Winterhalder, R ^c   Madlung, A ^e   Rauch, D ^g   Saletti, P ^h   Widmer, L ^f   Borner, M ^a   Baertschi, D ^d   Yan, P ^a   Benhattar, J ^a   Leibundgut, E O ^e   Bougel, S ^a   Koeberle, D ⁱ  

^a Gastrointestinal Tumorcenter Zurich ^*  (Switzerland)

^b Szent Laszlo Hospital   (Hungary)

^c LUZERNER KANTONSSPITAL   (Switzerland)

^d SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f Hirslanden Hospital Zurich   (Switzerland)

^g Departement of Medicine   (Switzerland)

^h OSPEDALE SAN GIOVANNI   (Switzerland)

ⁱ CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Capecitabine; Chemoradiotherapy; Panitumumab; Radiotherapy; Rectal cancer; Wild type KRAS

Indexed keywords

CAPECITABINE; K RAS PROTEIN; PANITUMUMAB;

ACNE; ADD ON THERAPY; ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANASTOMOSIS LEAKAGE; APOPTOSIS; ARTICLE; BLADDER DYSFUNCTION; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ERECTILE DYSFUNCTION; ERYTHEMA MULTIFORME; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FISTULA; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LOCALLY ADVANCED CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SKIN TOXICITY; TREATMENT RESPONSE; ULCER;

EID: 84874560532     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds519     Document Type: Article

References (45)

1. Bosset JF, Collette L, Calais G et al.. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
2. Klaassen RA, Nieuwenhuijzen GA, Martijn H et al.. Treatment of locally advanced rectal cancer. Surg Oncol 2004; 13: 137-147.
3. Sauer R, Becker H, Hohenberger W et al.. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
4. Gerard JP, Azria D, Gourgou-Bourgade S et al.. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-1644.
5. Hofheinz R, Wenz FK, Post S et al. Capecitabine (Cape) versus 5-fluorouracil (5- FU)-based (neo) adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): long-term results of a randomized, phase III trial. J Clin Oncol 2011; 29: (suppl; abstr 3504) 2011.
6. Cunningham D, Humblet Y, Siena S et al.. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
7. Douillard JY, Siena S, Cassidy J et al.. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
8. Jonker DJ, O'Callaghan CJ, Karapetis CS et al.. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
9. Peeters M, Price TJ, Cervantes A et al.. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713.
10. Bokemeyer C, Bondarenko I, Makhson A et al.. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
11. Bonner JA, Maihle NJ, Folven BR et al.. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 1994; 29: 243-247.
12. Liang K, Ang KK, Milas L et al.. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003; 57: 246-254.
13. Bonner JA, Harari PM, Giralt J et al.. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
14. Bonner JA, Harari PM, Giralt J et al.. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
15. Amado RG, Wolf M, Peeters M et al.. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
16. Karapetis CS, Khambata-Ford S, Jonker DJ et al.. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
17. Siena S, Sartore-Bianchi A, Di Nicolantonio F et al.. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324.
18. Di Nicolantonio F, Martini M, Molinari F et al.. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
19. De Roock W, Claes B, Bernasconi D et al.. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
20. Sartore-Bianchi A, Moroni M, Veronese S et al.. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-3245.
21. Khambata-Ford S, Garrett CR, Meropol NJ et al.. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
22. Greene LP, Balch CM, Fleming ID et al.. AJCC Cancer Staging Manual, 6th edition. New York: Springer 2002.
23. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23.
24. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
25. Bertolini F, Chiara S, Bengala C et al.. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2009; 73: 466-472.
26. Eisterer W, De Vries A, Oefner D et al.. Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03. J Clin Oncol 2009; 27:15S; Proc ASCO, A4109.
27. Horisberger K, Treschl A, Mai S et al.. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009; 74: 1487-1493.
28. Machiels JP, Sempoux C, Scalliet P et al.. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007; 18: 738-744.
29. Rodel C, Arnold D, Hipp M et al.. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008; 70: 1081-1086.
30. Velenik V, Ocvirk J, Oblak I et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol 2010; 36: 244-250.
31. Kim SY, Hong YS, Kim DY et al.. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter phase II study. Int J Radiat Oncol Biol Phys 2010; 81(3): 677-683.
32. Pinto C, Di Fabio F, Maiello E et al.. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol 2011; 22(11): 2424-2430.
33. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer (version 3. 2011). www.nccn.org. Last accessed 29 March 2011.
34. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer (version 4. 2011). www.nccn.org. Last accessed 29 March 2011.
35. Bengala C, Bettelli S, Bertolini F et al.. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 2009; 20: 469-474.
36. Debucquoy A, Haustermans K, Daemen A et al.. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009; 27: 2751-2757.
37. Gaedcke J, Grade M, Jung K et al.. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010; 94: 76-81.
38. Dewdney A, Cunningham D, Tabernero J et al.. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30(14): 1620-1627.
39. Beddy D, Hyland JM, Winter DC et al.. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol 2008; 15: 3471-3477.
40. Guillem JG, Chessin DB, Cohen AM et al.. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005; 241: 829-836; discussion 836-828.
41. Lacouture ME, Mitchell EP, Piperdi B et al.. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351-1357.
42. Law WI, Chu KW, Ho JW et al. Risk factors for anastomotic leakage after low anterior resection with total mesorectal excision. Am J Surg 2000; 179: 92-96.
43. Nesbakken A, Nygaard K, Lunde OC. Outcome and late functional results after anastomotic leakage following mesorectal excision for rectal cancer. Br J Surg 2001; 88: 400-404.
44. Rullier E, Laurent C, Garrelon JL et al.. Risk factors for anastomotic leakage after resection of rectal cancer. Br J Surg 1998; 85: 355-358.
45. Kalady MF, Dejulius KL, Sanchez JA et al.. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 2012; 55: 128-133.